Arvinas, Inc. (ARVN) News

Arvinas, Inc. (ARVN): $57.99

2.19 (+3.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ARVN News Items

ARVN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ARVN News Highlights

  • ARVN's 30 day story count now stands at 13.
  • Over the past 24 days, the trend for ARVN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • CONN, AR and DRUG are the most mentioned tickers in articles about ARVN.

Latest ARVN News From Around the Web

Below are the latest news stories about Arvinas Inc that investors may wish to consider to help them evaluate ARVN as an investment opportunity.

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer

– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA50 rate and durable RECIST responses – – Data support the potential for an accelerated approval pathway in a molecularly defined patient population, and the Company intends to initiate a pivotal trial by year end 2022 – – Anti-tumor activity seen across all subgroups of the ongoing Phase 2 ARDENT trial in patients who had progressed after treatment with novel horm

Yahoo | February 17, 2022

Despite shrinking by US$144m in the past week, Arvinas (NASDAQ:ARVN) shareholders are still up 227% over 3 years

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

Yahoo | February 17, 2022

3 Stocks To Double Down On In 2022

The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination of the omicron fears, and the anticipation of the Fed raising rates to curb the surge of inflation. This has led to a growing concern about the possibility of a bear market this year. However, Goldman Sachs chief global equity strategist Peter Oppenheimer believes it''s time to buy. “Any further significant weakness at the index level should be seen as a buying opportunity, in our view, albeit with moderate upside through the year as a whole,” he recently wrote. Analysts at Goldman have set their sights on three stocks they believe will tower 70% or more this year: Arvinas Inc. (NASDAQ: ARVN ): Arvinas is a clinical-stage biophar...

Benzinga | February 16, 2022

Leerink Partners Maintains a Buy Rating on Arvinas Holding Company (ARVN)

In a report released today, Christopher Liu from Leerink Partners maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report). The company's shares closed last Tuesday at $76.54. According to TipRanks.com, Liu is ranked 0 out of 5 stars with an average return of -20.9% and a 20.0% success rate. Liu covers the Healthcare sector, focusing on stocks such as Monte Rosa Therapeutics, Nurix Therapeutics, and Cogent Biosciences. Currently, the analyst consensus on Arvinas Holding Company is a Strong Buy with an average price target of $134.40, implying a 77.9% upside from current levels.

Brian Anderson on TipRanks | February 15, 2022

Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients

Arvinas Inc (NASDAQ: ARVN ) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide (ARV-110). The data were shared at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium. The data showed that bavdegalutamide continues to provide evidence of anti-tumor activity and patient benefit in metastatic castration-resistant … Full story available on Benzinga.com

Benzinga | February 15, 2022

Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting

– Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations – – Arvinas plans to initiate a pivotal trial by year end 2022 evaluating bavdegalutamide in patients with mCRPC who have progressed on or after novel hormonal agents (NHAs) and have tumors that harbor AR T878X/H875Y mutations – – Updated data to be presented in a rapid abstract session and a poster session at ASCO GU and

Yahoo | February 14, 2022

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

I find Arvinas (ARVN) very interesting because it offers a new kind of drug development completely different from - and avoiding the limitations of - traditional small molecules and molecular antibodies. This new technology can be called induced protein degradation. Arvinas is a pioneering protein degrader with strong early data,...

Avisol Capital Partners on Seeking Alpha | February 7, 2022

Arvinas to Present at Upcoming Investor Conferences

NEW HAVEN, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences:

GlobeNewswire | February 3, 2022

Goldman Sachs Bets on These 3 “Strong Buy” Stocks

The stock market’s recent meltdown has been based on a potent combination of omicron fears, rising inflation, and the prospect of the Fed hiking rates at a rapid pace in an effort to curb the surge. As such, the real prospect of a bear market has reared its ugly head. However, Goldman Sachs’ chief global equity strategist Peter Oppenheimer does not think it is time to sound the alarm; Oppenheimer believes any rate hikes this year won’t be too steep. This should mark the current period as a corre

Yahoo | January 31, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4556 seconds.